Stuttgart
06.06.25 | 10:50
63,00 Euro
0,00 % 0,00
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | DSM-Firmenich schliesst Verkauf von Feed Enzymes Alliance an Novonesis ab | 12 | cash | ||
| Mo | dsm-firmenich completes sale of its stake in Feed Enzymes Alliance to Novonesis for €1.5 billion | 344 | GlobeNewswire (Europe) | Press Release
dsm-firmenich completes sale of its stake in Feed Enzymes Alliance to Novonesis for €1.5 billion
Kaiseraugst (Switzerland), Maastricht (Netherlands), June 2, 2025
dsm-firmenich... ► Artikel lesen | |
| Mo | Novonesis (Novozymes A/S): Novonesis completes acquisition of dsm-firmenichs's share of the Feed Enzyme Alliance | 4 | GlobeNewswire (USA) | ||
| Mo | Novonesis (Novozymes A/S): Transactions under Novonesis' share buyback program | 2 | GlobeNewswire (USA) | ||
| 29.05. | Morgan Stanley stuft Novonesis-Aktie mit Kursziel von 577,00 DKK als Overweight ein | 8 | Investing.com Deutsch | ||
| NOVONESIS A/S ADR Aktie jetzt für 0€ handeln | |||||
| 29.05. | Morgan Stanley sets Novonesis stock Overweight with DKK577 target | 4 | Investing.com | ||
| 29.05. | MS starts Novonesis at Overweight, says stock to rerate towards its prior highs | 2 | Investing.com | ||
| 28.05. | UBS upgrades Novonesis to "buy," cuts Kerry to "neutral" on growth outlook | 3 | Investing.com | ||
| 27.05. | UBS lifts Novonesis stock rating to Buy, target to DKK530 | 4 | Investing.com | ||
| 27.05. | UBS hebt Novonesis-Bewertung auf Kaufen an, Kursziel auf 530 DKK | 5 | Investing.com Deutsch | ||
| 26.05. | Novonesis (Novozymes A/S): Transactions under Novonesis' share buyback program | 2 | GlobeNewswire (USA) | ||
| 19.05. | Novonesis (Novozymes A/S): Combining EVP roles of Human Health Biosolutions and Strategy & Integration | 4 | GlobeNewswire (USA) | ||
| 19.05. | Novonesis (Novozymes A/S): Transactions under Novonesis' share buyback program | 5 | GlobeNewswire (USA) | ||
| 12.05. | Novonesis (Novozymes A/S): Transactions under Novonesis' share buyback program | 2 | GlobeNewswire (USA) | ||
| 12.05. | Novonesis (Novozymes A/S): Trading by management and close relations of management | 2 | GlobeNewswire (USA) | ||
| 09.05. | Novonesis A/S GAAP EPS of €0.40, revenue of €1.08B | 12 | Seeking Alpha | ||
| 08.05. | Novonesis (Novozymes A/S): Novonesis delivered a strong Q1 with 11% organic growth and confirms full-year outlook | 439 | GlobeNewswire (Europe) | COPENHAGEN, Denmark - May 8, 2025. The global leader in biosolutions, Novonesis, had a strong start to its financial year with organic sales growth of 11% and an adjusted EBITDA margin of 38.3%. The... ► Artikel lesen | |
| 08.05. | Novonesis (Novozymes A/S): Interim report Q1 2025 | 237 | GlobeNewswire (Europe) | Strong start to the year and confirmed full-year outlook Ester Baiget, President & CEO: "We delivered strong sales growth and earnings in the first quarter, with all four sales areas showing double-digit... ► Artikel lesen | |
| 05.05. | Novonesis (Novozymes A/S): Transactions under Novonesis' share buyback program | 6 | GlobeNewswire (USA) | ||
| 28.04. | Novonesis (Novozymes A/S): Transactions under Novonesis' share buyback program | 5 | GlobeNewswire (USA) |
1 2 3 Weiter >>
50 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| GENMAB | 193,95 | -0,69 % | Genmab A/S: Genmab Announces Investigational Rinatabart Sesutecan (Rina-S) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL-01 Trial | New data showed that rinatabart sesutecan (Rina-S) 100 mg/m2 led to a confirmed objective response rate (ORR) of 50.0 percent, including two complete responses (CR), and median duration of response... ► Artikel lesen | |
| INSMED | 64,50 | -0,77 % | Insmed Incorporated: Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | BRIDGEWATER, N.J., June 4, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first-... ► Artikel lesen | |
| PHATHOM PHARMACEUTICALS | 8,920 | +90,19 % | Phathom Pharmaceuticals, Inc. - 8-K, Current Report | ||
| AVIDITY BIOSCIENCES | 36,240 | +1,83 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, May 21, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics... ► Artikel lesen | |
| QIAGEN | 40,060 | -0,55 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat das Kursziel für Qiagen von 47 auf 50 US-Dollar angehoben und die Einstufung auf "Buy" belassen. Analyst Jan Koch zog in seinem am Dienstag... ► Artikel lesen | |
| ARCELLX | 68,10 | +2,81 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 14,370 | +6,37 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| RECURSION PHARMACEUTICALS | 5,485 | +20,02 % | Recursion Pharmaceuticals shares surge on AI model release | ||
| TARSUS PHARMACEUTICALS | 43,920 | -0,39 % | Oppenheimer assumes Tarsus stock at outperform on strong sales | ||
| BIONTECH | 95,35 | +0,05 % | Summit Therapeutics crasht - BioNTech in Sippenhaft | Wie gewonnen, so zerronnen: Die Aktie von Summit Therapeutics brach am vergangenen Freitag an der Nasdaq um rund 30 Prozent ein. Weitere Studiendaten zum großen Hoffnungsträger Ivonescimab, den die... ► Artikel lesen | |
| VERA THERAPEUTICS | 22,760 | -25,69 % | Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy | Atacicept ORIGIN Phase 3 trial met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving atacicept achieved a 46% reduction from baseline and 42% reduction compared... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 46,880 | -3,99 % | ROUNDUP/Aktien New York: Knappes Plus - Gelassenheit trotz Zoll-Unruhen | NEW YORK (dpa-AFX) - Die US-Börsen haben am Dienstag knappe Kursgewinne erzielt. Die jüngst wieder aufflackernden, internationalen Handelsstreitigkeiten wegen der amerikanischen Zollpolitik scheinen... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 15,240 | +2,83 % | RBC Capital behält Outperform-Rating für Edgewise Therapeutics-Aktie bei | ||
| JANUX THERAPEUTICS | 26,210 | +5,86 % | Leerink cuts Janux Therapeutics price target to $89, keeps Outperform | ||
| EVOTEC | 7,060 | +0,94 % | Evotec Aktie: Ohne Übernahme sieht es schlecht aus! Auf diese Kursmarke kommt es an! | © Foto: Finanznachrichten (Symbolbild)Zwischen Kursrakete mit Übernahmefantasie und Korrekturmodus Richtung Süden. Der Biotech-Titel aus Hamburg liefert seit Wochen ein Wechselbad der Gefühle. Kann... ► Artikel lesen |
Das Unternehmen NOVONESIS A/S ADR kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 63,00 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NOVONESIS A/S ADR finden Sie auf Wallstreet Online.